Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
Pharmaceutical
Sentynl Therapeutics, wholly owned by Zydus Lifesciences, has announced that the US Food and Drug Administration has accepted its New Drug Application for CUTX-101, a potential first treatment for Menkes disease. The application has been granted priority review, with a target action date set for June 30, 2025. 7 January 2025
All news
Pharmaceutical
An agreement between the University of Hong Kong and the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB) will pave the way for the establishment of a new research institute dedicated to tackling infectious diseases. 3 November 2023
Pharmaceutical
The American business of Israeli drugmaker Teva Pharmaceutical has announced new Huntington’s disease (HD) data to be presented at the ongoing Huntington Study Group annual meeting. 3 November 2023
Pharmaceutical
AstraZeneca has presented positive results from the real-world ZORA trial, at the annual congress of the American Society of Nephrology (ASN). 3 November 2023
Pharmaceutical
An Expert View from Bradley Hardiman, Senior Director, Astellas Venture Management. 3 November 2023
Pharmaceutical
US ophthalmic drug developer Aldeyra Therapeutics saw its shares leap 48.5% to $2.54 yesterday after it announced the signing of a deal with pharma major AbbVie 2 November 2023
Pharmaceutical
Phathom Pharmaceuticals has received approval from the US regulator for a reformulation of its oral vonoprazan products. 2 November 2023
Pharmaceutical
A new first-in-class antibiotic, zoliflodacin, has been shown to be effective in the treatment of gonorrhea, in a Phase III trial. 2 November 2023
Pharmaceutical
US ophthalmic drug developer Ocuphire Pharma has appointed Dr George Magrath, as chief executive and member of the board of directors, effective today. 2 November 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk today reported record sales and operating profits for the third quarter of 2023, but cautioned it would keep in place restrictions on supplies of its much in demand Wegovy(semaglutide) weight-loss drug. 2 November 2023
Pharmaceutical
British pharma major GSK has surpassed market expectations, announcing a 10% increase in total sales, and a 16% rise when excluding COVID-19 impacts. 1 November 2023
Pharmaceutical
Shares of Japanese pharm major Shionogi rose 2.4% to 7,152 yen, as the company announced a $150 million transaction with US clinical-stage firm Apnimed. 1 November 2023
Pharmaceutical
UK pharma major GSK and Arrowhead Pharmaceuticals today announced an agreement for GSK to obtain an exclusive license for JNJ-3989 (formerly ARO-HBV) for treatment of chronic hepatitis B. 31 October 2023
Pharmaceutical
US pharma giant Pfizer was trading more than 1% lower during Tuesday morning’s trading in New York, following the release of financial results. 31 October 2023
Pharmaceutical
Shares Japanese drugmaker Sosei Heptares rose 4% to 1,390 yen today, after it announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of daridorexant (ACT-541468). 31 October 2023
Pharmaceutical
Russian pharmaceutical manufacturers have increased the number of clinical trials that are conducted in the domestic market as part of their efforts of import substitution, The Pharma Letter’s local correspondent reports. 31 October 2023
Pharmaceutical
Swiss pharma giant Novartis has announced positive top-line results from the interim analysis of the ongoing pivotal Phase III ALIGN study of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgA nephropathy (IgAN). 30 October 2023
Pharmaceutical
Privately-held Italian drugmaker Chiesi today announced the appointment of Ralph Blom as the general manager for Chiesi Limited (covering the UK and Ireland), beginning January 2024. 30 October 2023
Pharmaceutical
The Global Health Innovative Technology (GHIT) Fund and United Nations-backed Medicines Patent have signed a Memorandum of Understanding (MOU) to strengthen their collaboration to improve access to medicines. 30 October 2023
Pharmaceutical
French drugmaker Ipsen has presented its sales performance for the year-to-date 2023. 30 October 2023
Pharmaceutical
As it works to transition the COVID-19 oral antiviral treatments from government distribution to traditional health care distribution channels, US Health and Human Services (HHS) Secretary Xavier Becerra on Friday issued a request a request on the agency’s website for ongoing partnership during and after this transition. 28 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze